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ABSTRACT

OBJECTIVE: The objective of this systematic review is to determine whether or not
Vitamin E is effective in reducing the mortality related to cardiovascular event in
patients with Type 2 Diabetes mellitus.
STUDY DESIGN: Review of three English language primary studies published from
2004 to 2010.
DATA SCOURCE: Randomized, double blind, placebo-controlled trails comparing
Vitamin E to Vitamin C, n-polyunsaturated fatty acid and placebo were found using
Ovid MEDLINE and Cochrane database
OUTCOME MEASURED: The primary outcomes measure by all three studies included 30day cardiac mortality, mortality due to CHF and nonfatal myocardial infarction and
stroke. The secondary outcomes measured in the studies included hospitalization forCHF
and coronary revascularization
RESULTS: Three double-blind randomized controlled trails were incorporated in
this review. Study by Milman et al showed that Vitamin E supplementation is
beneficial compared to the placebo group. The second study by Jaxa-Chameic et al.
showed that Vitamin E is beneficial along with Vitamin C but is not effective when
used alone. The third study by Marchioli et al. showed that Vitamin E treatment has
a statistically nonsignificant (p = 0.18) increased risk of developing CHF.
CONCLUSIONS: The result of one ofthe three RCT's showed that use of Vitamin E
supplementation provides cardiovascular benefits in diabetic population with Hp 22 genotype. The other two studies showed worse effects or no conclusive effects
with Vitamin E supplementation. The study population with favorable outcome with
Vitamin E supplementation included Diabetic patients with Hp 2-2 genotype. Hence,
further studies must be conducted in population with Hp 2-2 genotype to conclude
the effects of Vitamin E.
KEY WORDS: Vitamin E, antioxidants, Myocardial Infarction, Diabetes Mellitus,
Prophylaxis
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INTRODUCTION

Cardiovascular disease is a major cause of morbidity and mortality in patients with
Type 2 Diabetes Mellitus (T2DM). T2DM is the most common form of metabolic disorder
commonly seen in obese population.! Diabetic patients are chronically exposed to high
blood glucose levels which in the long run leads to increased deposits of lipids in the intima
of the blood vessels. These deposits lead to narrowing of the vessel, affecting the blood flow
and ultimately resulting in an increased risk of clogging and hardening of the vessels.
Hyperlipidemia, also commonly seen in diabetic patients, leads to atherosclerotic changes
of the arteries of the heart causing coronary artery disease (CAD), the most common cause
of acute myocardial infarction (AMI) and congestive heart failure (CHF).
Diabetes Mellitus is an independent risk factor of cardiovascular diseases and tends
to develop heart disease and stoke at an earlier age.! In the article by Jaxa-Chamiec, it is
proposed that reactive oxygen species (ROS) along with hyperglycemia plays a crucial role

t

"

in endothelial dysfunction, ischemia reperfusion injury and pathogenesis of DM.2
Endothelial dysfunction leads to decreased production of nitric oxide (NO). NO is an
endothelium-derived relaxing factor (EDRF) which signals smooth muscle to relax causing
vasodilation of the blood vessel. Hence, decrease in NO causes vasoconstriction and
decrease perfuSion to organs and tissues. Population with diabetes, hypertension and
atherosclerosis are noted to have decreased amount of NO. In 2004, death due to
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cardiovascular complication in diabetic population of ages 65 years or older was around
68%.1

Diabetic population has atypical presentation of AMI or no symptoms due to
autonomic nerve dysfunction known as "silent heart attack". The classic presentation of

;
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AMI includes symptoms of severe substernal chest pain/pressure sometime radiating to
the left upper extremity, jaw or shoulder; nausea, vomiting, diaphoresis, dizziness,
shortness of breath or general malaise. The heart myocardium is damaged in MI leading to
decreased compliance of the heart ultimately reducing the contractility and stroke volume.
AMI is the common cause of heart failure. The population with CHF requires frequent
hospitalizations increasing the cost of care. In United States, between 2009 - 2034, cost of
care for cardiovascular disease is estimated to increase from $113 billion to $336 billion. 1
Since there is no definite treatment for cardiovascular complications in diabetic patients,
most of the money is spend to prevent further complications and to stabilize patient's
condition.
T2DM is a chronic disease that requires constant monitoring and drug intervention.
T2DM population receives aspirin, clopidogrel, B-blocker to prevent AMI or stroke and
receive Angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers
(ARBs), B-blockers, digoxin, and diuretics in various combinations to control the severity of
the heart failure. 2 However, the diabetic population is not treated to reduce the reactive
oxidative species (ROS), which leads to endothelial damage. Vitamin E is known to have an
antioxidant property that is theoretically known to decrease ROS levels and hence the
study was proposed to see the effects of Vitamin E on cardiovascular disease in diabetic
patients.
The topic of study is important to health care providers working in any specialty
because diabetes is a common condition today with high rates of incidence and prevalence.
It is proposed that between 2009-2034, diabetic patients will increase from 23.7 million to 44.1
million,! Also, if the study intervention shows to have positive effects in T2DM patients, the

.,,
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cost associated with care in this population can be reduced. If supplemental Vitamin E
shows to reduce the incidence of AMI and severity of CHF, it will reduce the cardiovascular
related hospitalization cost in T2DM population.

OBJECTIVE

The objective of this systematic review is to determine whether or not the use of
Vitamin E supplementation is effective in reducing the cardiovascular mortality in Type 2
Diabetes Mellitus (T2DM) patients.

METHODS

The three studies included in this review were based on a following criterion. The
population included individuals with Type 2 Diabetes Mellitus and acute myocardial
infarction with or without T2DM. Study by Milman et aL further classified the diabetic
population depending on their genotype: Haptoglobin (Hp). The study included the diabetic
patients with Hp 2-2 genotype only.
All studies excluded patients with uncontrolled hypertension, stroke within 1 month
before enrollment, unwillingness to stop antioxidants supplements, known allergy to
vitamin E. In addition, the study by Milman et aL excluded diabetic population with Hp 1-1
and Hp 2-1 genotype; Jaxa-Chamiec et aL excluded the death due to non-cardiac related
cause and Marchioli et aL excluded population with baseline CHF managed by multiple
drug regimen.
The intervention used in the studies was Vitamin E 300 mg/ day (Marchioli et aLl,
600 mg/day (Jaxa-Chamiec et aL) and 400 IU/day (Milman et aLl. The treatment groups
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were compared to the control groups who were given visually matched n-polyunsaturated
fatty acid 19/day (Marchioli et al.), Vitamin C 1200 mg/day (Jaxa-Chamiec et al.) and
placebo. The main outcomes measured were mortality related to cardiovascular events,
risk of developing CHF and hospitalization for cardiovascular complication (PEOM). The
studies were double blind, randomized, and placebo-controlled.
The study performed by Jaxa-Chamiec et al. were given infusion and oral Vitamin E
and Vitamin C together and other group on the study was given infusion of saline placebo. 2
In the study performed by Marchioli et al. the population was divided into four
groups who were given Vitamin E, n-polyunsaturated fatty acids, both or none respectively
and were followed for 3.5 years.3 Echocardiographic measure ofleft ventricular ejection
fraction was determined and patients developing CHF were defined as "hospitalization or
death for CHF".3
The study performed by Milman et al. took place within 47 primary health care
clinics in the Haifa and Western Galilee district of Clalit Health Services. 4 Hp phenotyping
was performed by electrophoresis and diabetic population with Hp 2-2 were selected. A
computer generated randomization was used to divide study population into 2 groups
from with one group received Vitamin E and another group received placebo. 4
Key words used in literature searches were vitamin E, antioxidant, congestive heart
failure, myocardial infarction, diabetes mellitus and oxidative stress. All articles were
published in English language in the peer-reviewed journals. Articles used in the review
were searched and selected by the author using literature searches like Ovid, Medline and
Cochrane. Articles were selected based on their relevance and outcomes. The studies
included are conducted in randomized, controlled fashion in a prospective, intention to
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treat basis, date after 2004 or later. The statistics utilized in the studies were p-value,
confidence interval (CI), relative risk reduction (RRR), absolute risk reduction (ARR) and
number needed to treat (NNT).

Ta bl e 1 - Demograplh·ICS &Ch aractenstlcs 0 f·mcIu d e d stu d·les
CHARACTERISTICS OF STUDIES INCLUDED IN SYSTEMATIC REVIEW OF THE
ADDITION OF VITAMIN E IN THE REGIMEN OF MYOCARDIAL INFARCTION
Study

. JaxaChamiec,
2005 (1)

Marchioli
2006 (2)

Milman,
2008 (3)

Type

#Pts

Age
(yrs)

Inclusion
criteria

Exclusion
Criteria

WID

Intervention

Randomized,
placebocontrolled
double-blind
clinical study

800

50 75

Documented
non-cardiac
cause

0

VitaminE
600 mg/day;

Open label,
randomized,
clinical trial

8415

In-hospital or
out-hospital
cardiac
mortality in
patients with
or without
diabetes
mellitus
No diagnosis
of heart
failure and
an
echocardiographic
measurement
of Ejection
Fraction (EF)
at baseline

Prospective,
Doubleblinded
clinical trial

1434

45 70

;:0:55

;:0:55 yo
T2DM and
Hp2-2
genotype,

Vitamin C
1200
mg/day

Heart failure at 220
baseline; use of
angiotensinconverting
enzyme
inhibitors,
B-blockers,
diuretics or
nitrates for
CHF
management.
Hp I-I & 2-1
136
genotypes;
Uncontrolled
hypertension;
MI or stroke
within 1 month
before
enrollment;
unwillingness
to stop
antioxidant
supplements;
Known allergy
to Vitamin E

VitaminE
300 mg/day;
n-3
polyunsatur
ated fatty
acids I g/day

VitaminE
400 IU/day;
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OUTCOME MEASURED

The primary outcome measured was incidence of the cardiovascular morbidity and
mortality in the study population. Jaxa-Chamiec et al. measured the primary outcome based on
30-day cardiac mortality in-hospital or out-hospital. Marchioli et al. measured the risk of
developing congestive heart failure by performing echocardiogram measurement of the ejection
fraction and defined the population developing CHF during the study as "death or hospitalization
due to CHF". Study performed by Milman measured primary outcome based on composite of
cardiovascular death, nonfatal myocardial infarction and stroke. Milman also measured the
secondary outcomes, which included total mortality, hospitalization for congestive heart failure
and coronary revascularization.

RESULTS
The results pertaining to the primary outcome were documented as dichotomus data in all
three studies. The data from the studies was published as an intention to treat analysis with the
exception of participants who did not participate till the end of the study or those who were lost
to follow-up or incompliant.
Jaxa-Chamiec et al. reported cardiovascular mortality of 8% and 22% in the Vitamin E
and control groups (Vitamin C), respectively. This difference is statistically significant (p =
0.036). The absolute risk reduction (ARR) was calculated to be 14% and the relative risk
reduction (RRR) was 175%. This study determined that munber needed to treat (NNT) was 7
patients using the dosage of 600 mg/day (Table 2).
Marchioli et al. reported hospitalization and death due to congestive heart failure of 4.7%
and 2.2% in the Vitamin E and control groups (n-polyunsaturated fatty acid), respectively. This
difference is statistically nonsignificant (p = 0.18). The treatment with Vitamin E in this study
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showed increased risk of developing CHF. The absolute risk reduction (ARR) was calculated to
be 2.5% and the relative risk reduction (RRR) w~ 53%. This study determined that number
needed to treat (NNT) was 40 patients using the dosage of 300 mg/day (Tabie 2).
Milman et al. reported cardiovascular death, nonfatal myocardial infarction and stroke of
1.6% and 4.6% in the Vitamin E and control groups, respectively. This difference is statistically
significant (p

= 0.003). The absolute risk reduction CARR) was calculated to be 3% and the

relative risk reduction (RRR) was 187.5%. This study determined that number needed to treat
(NNT)

was 33 patients using the dosage of 400 IU/day (Table 2).

Table 2- Efficacy of Vitamin E in cardiovascular mortality
Study
Vitamin E
Control p-value
95%CI
group
group
(CEI{)
(EER)
Jaxa22%
0.036
8%
0.51 to 1.85
Chamiec

RRR

ARR

NNT

175%

14%

7

-2.5%

-40'

Marchioli

4.7%

2.2%

0.18

0.92 to 1.56

-53 %

Mi lman

1.6%

4.6%

0.003

0. 16 to 0.70

187.5% 3%

33

CI - Confidence Interval, RRR - Relative Risk ReductIOn, ARR - Absolute Risk ReductIOn,
NNT = Number Needed to Treat
*Since the outcome measured was incidence and severity ofcardiovascular disease, the negative
value for NNT indicates that for every 40 participants who took Vitamin E, there was one fewer
incidence of cardiovascular complication than in the group ofparticipants taking placebo

As seen in table 2 the Relative Risk Reduction (RRR) is high in both the Jaxa-Chamiec

;.

and Milman studies with 175% and 187.5% respectively, however the Marchioli study did not
show a similar reduction in cardiac mortality with a RRR of 53%. It is also reflected in numbers
needed to treat (NNT) for Marchioli study is higher compared to the other two studies.
If compared the doses of Vitamin E used in the three studies, it appears that JaxaChamiec utilized dose of 600 mg/day is approximately five to six times more effective with a

,
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NNT value of7 compared to dose of 300 mg/day and 400 IU/day used by Marchioli and Milman
with a NNT value of 40 and 33 respectively. However, there is no data in study that mentions
compares the dosage of Vitamin E.
Secondary end points measured in the study by Milman et al. did not show significant
difference in the group treated with Vitamin E compared to the placebo. The results for the
secondary end points are listed in Table 3.

I . 0 fTreatmento ut comes.
Table 3 Second ary EndP'
omtA nalYS1S
End points

VitaminE

Placebo

PValue

RRR

ARR

NNT

Revascularization

11 (1.5%)

18 (2.5%)

0.17

66%

1%

1

Congestive Heart Failure

8 (1.1%)

8 (1.1%)

0.96

0

0

0

Total Mortality

11 (1.5%)

12 (1.7%)

0.77

13%

0.2%

5

The studies chosen for this review had certain limitations. The study did not include all
the participants in the results as some were excluded from the study. In the study by Milman et
aI.136 were not included in the results: two were lost to follow up; seven due to their physician's
advice; eleven due to side effects, 116 were noncompliant based on telephone interviews. Also,
in this study, no attempt was made to optimize or manage the medication prescribed by the
primary care physician. Limitation to Jaxa-Chamiec et aI. study is the retrospective mode of
analysis performed on the diabetic patient subgroup and the secondary analysis (effects of
antioxidant Vitamins on patients older than age 70, anterior myocardial infarction, and symptoms
of AMI for> 12) did not reach significance and hence failed to support the primary hypothesis of
the study.
All the clinical trials have failed to test the basic foundation underlying the hypothesis,
which is the capacity of the antioxidant to reduce the oxidative stress. None of the studies
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measure the oxidative states in the study population, it is impossible to determine the effect of
antioxidant supplement without knowing the initial oxidative stress a person is experiencing. It is
hard to show the effect of a substance without determining what it is actually having the effect
on in the first place.

DISCUSSION
Oxidative modification by reactive oxidative species (ROS) oflow-density lipoprotein is
an important step in the development and progression of atherosclerotic plaque. ROS are found
in high quantity in hyperglycemic state of diabetic patients. Increased oxidative stress has been
linked to impaired endothelial function.2 Vitamin E has antioxidant properties that help reduce
ROS formation, in turn inhibit the formation of atherosclerotic plaque. Reduction in the
formation of atherosclerotic and endothelial damage can reduce cardiovascular damage in
diabetic popUlation.
According to the study Marchioli et aI., there is a significant relation between plasma
oxidized low-density lipoprotein and severity as well as worsening ejection fraction and higher
level of neurohormonal activation in patients with CHF? However, it's effect were not
reproducible in the study which concluded that Vitamin E leads to depression of myocardial
function and hospitalization and death in CHF. Hence, Vitamin E did not show a beneficial role
in prevention of congestive heart failure after a myocardial infarction
However, the study on Diabetic population with Hp 2-2 genotype by laxa-Chamiec et al
showed cardiovascular benefits form Vitamin E supplementation. It was concluded that Vitamin
E reduced cardiovascular death and AMI in the specific population with Hp 2-2 genotype.

:/
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CONCLUSION

According Marchioli et al. Vitamin E has deleterious effect on cardiovascular outcomes,
particularly late-onset heart failure? The study showed a statistically nonsignificant increased
risk of developing CHF due to depression of left ventricular function with addition of Vitamin E
supplementation to their therapy. According to Jaxa-Chamiec et al. antioxidative property of
Vitamin E significantly reduces a 30-day mortality in diabetic patients with recent MI but the
secondary analysis in a trail failed to support its primary hypothesis and the validity of the trail is
questionable. However, according to Milman et al. Vitamin E provides cardiovascular benefit to
diabetic individuals with the Hp 2-2 genotype. Vitamin E supplementation in this population has
shown to reduce cardiovascular death and myocardial infarction.
Hence, it can be conclude that Vitamin E is effective in diabetic patients with Hp 2-2
genotype and can have adverse effect in non-diabetic population. Future research should be
designed to study the effect of Vitamin E in Hp 2-2 genotype diabetic patients. The research of
further studies will implement the use if Vitamin E in specific diabetic population. The use of
Vitamin E in this population can reduce the cost and cardiovascular complications in diabetic
population.
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